Request Demo

Last update 08 May 2025

Glyburide

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide

+ [23]

Target

BSEP x Kir6.2 x SUR1

Action

inhibitors, agonists

Mechanism

BSEP inhibitors(ATP binding cassette subfamily B member 11 inhibitors), Kir6.2 agonists(potassium inwardly rectifying channel subfamily J member 11 agonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseOther DiseasesNeoplasms+ [1]

Active Indication

Inactive Indication

Brain ConcussionBrain ContusionBrain Edema+ [5]

Originator Organization

Pfizer Inc.

Active Organization

Sanofi-Aventis U.S. LLC

Pfizer Inc.Ammtek Ltd.

+ [3]

Inactive Organization

Remedy Pharmaceuticals, Inc.

Biogen, Inc.

Jiangsu Aosaikang Pharmaceutical Co. Ltd.

+ [1]

License Organization

Biogen, Inc.

Eton Pharmaceuticals, Inc.

Remedy Pharmaceuticals, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

Japan (02 Mar 1971),

Diabetes Mellitus, Type 2

RegulationOrphan Drug (European Union), Priority Review (China)

Structure/Sequence

Molecular FormulaC23H28ClN3O5S

InChIKeyZNNLBTZKUZBEKO-UHFFFAOYSA-N

CAS Registry10238-21-8

Clinical Trials associated with Glyburide

NCT06589141

/ Not yet recruitingNot ApplicableIIT

Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes: a Randomized Controlled Trial (GDM-MERGE Trial)

This study aims to compare the maternal, fetal, and neonatal outcomes associated with the use of metformin versus glyburide for managing gestational diabetes.
The objective is to assess the safety and effectiveness profiles of both medications as potential alternatives to initiating insulin therapy.

Start Date01 Jan 2025

Sponsor / Collaborator

Assiut University

CTRI/2023/12/060716

/ RecruitingNot ApplicableIIT

Role of Sulphonylurea-receptor1(SUR1) inhibition in Traumatic Brain injury (TBI): A randomized controlled trial to assess efficacy and safety of Glibenclamide in moderate to severe TBI - STRATEGY

Start Date01 Jan 2024

Sponsor / Collaborator

Indian Council of Medical Research

NCT05687500

/ RecruitingPhase 2IIT

Oral Glibenclamide in Preterm Infants with Hyperglycaemia (GALOP)

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Start Date20 May 2023

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

100 Clinical Results associated with Glyburide

100 Translational Medicine associated with Glyburide

100 Patents (Medical) associated with Glyburide

16,030

Literatures (Medical) associated with Glyburide

01 Aug 2025·Microbial Pathogenesis

A new target for drug repositioning: CEBPα elicits LL-37 expression in a vitamin D-independent manner promoting Mtb clearance

Article

Author: González-Muñiz, Óscar E ; Félix-Arellano, Camelia ; Santos-Mena, Alan ; Navarro-Tovar, Gabriela ; Rodríguez-Carlos, Adrián ; Rivas-Santiago, Bruno ; Jacobo-Delgado, Yolanda M

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (Mtb) and is a growing public health problem worldwide. Within the innate immune response, we highlight the secretion of the antimicrobial peptide LL-37, which is crucial for Mtb elimination in infected cells. Previous reports have shown that CEBPα activation induces LL-37 independently of its main inducer, vitamin D, under endoplasmic reticulum (ER) stress. In this study, we report that infection with Mtb causes ER stress in pulmonary epithelial cells and macrophages. The stress induces the activation of CEBPα, which in turn promotes the LL-37 expression. Furthermore, the participation of CEBPα is necessary for the correct clearance of Mtb in an in vitro infection model. We identify candidate drugs (mycophenolic acid, indapamide, and glibenclamide) capable of activating CEBPα and promoting LL-37 through in silico assays. The effect of the drugs was corroborated by gene and protein expression analysis. Finally, we observed that treatment with these drugs improves bacterial clearance in infected cells. Our results lead us to suggest CEBPα as a potential therapeutic target as an adjuvant in the standard treatment of tuberculosis, seeking a reduction in treatment time, and thus a lower appearance of drug resistance.

01 Jul 2025·Archives of Biochemistry and Biophysics

A glibenclamide analog lacking the cyclohexylurea portion fails to block ischemic preconditioning-induced mitochondrial and cardiac protection against ischemia/reperfusion injury

Article

Author: de Freitas Soares, Geovanna Carvalho ; Palácio, Plínio Bezerra ; Facundo, Heberty Tarso

Despite significant research, there are no definitive therapies to prevent ischemia/reperfusion injury. During reperfusion, mitochondrial reactive oxygen species (ROS) cause cell damage. Ischemic preconditioning (IP), characterized by brief cycles of ischemia and reperfusion, activates mitochondrial ATP-sensitive potassium channels (mitoKATP) and provides cardioprotection. The aim of the present study is to investigate the impact of a truncated glibenclamide (lacking the cyclohexylurea portion - IMP-A) in ischemic preconditioning (IP)-mediated cardioprotection. Our study shows that IMP-A (2-5 μM) does not inhibit the protective effects of IP against ischemia/reperfusion damage in isolated rat hearts. In this context, IP hearts (with or without IMP-A) exhibited preserved cardiac function, as indicated by stable left ventricular developed pressure, maximal and minimal first derivatives, and rate-pressure product, along with a reduced infarct size following ischemia/reperfusion injury. Conversely, glibenclamide (2 μM - a well-characterized mitoKATP inhibitor) abolished the protective effects of IP against ischemia/reperfusion damage. Mitochondria isolated from reperfused IP hearts (treated or not with IMP-A) produced significantly lower levels of mitochondrial ROS and had lower susceptibility to Ca²⁺-induced swelling secondary to mitochondrial permeability transition pore (mPTP) opening. Additionally, IP hearts (treated or not with IMP-A) had preserved protein sulfhydryls. Glibenclamide elevated mitochondrial ROS production and negatively impacted mPTP and the sulfhydryl protection seen in IP hearts. Importantly, mitochondrial O₂ consumption was preserved in IP hearts (treated or not with IMP-A), and this preservation was disrupted by glibenclamide but not by IMP-A. These findings suggest that the cyclohexylurea group of glibenclamide is essential for its ability to block IP-mediated cardioprotection, providing valuable insights for developing novel therapeutic strategies.

01 Jun 2025·European Journal of Pharmacology

The sodium-glucose cotransporter 2 inhibitor tofogliflozin induces vasodilation of rabbit femoral artery by activating Kv channels, the SERCA pump, and the sGC/cGMP pathway

Article

Author: Kim, Hye Ryung ; An, Jin Ryeol ; Jung, Won-Kyo ; Seo, Mi Seon ; Jeong, Junsu ; Park, Minju ; Park, Hongzoo ; Jang, YeEun ; Park, Won Sun ; Zhuang, Wenwen ; Choi, Il-Whan

Tofogliflozin is a sodium-glucose cotransporter 2 inhibitor widely used to treat type 2 diabetes mellitus, but it also exhibits cardio-protective effects. This study investigated the vasodilatory action of tofogliflozin using rabbit femoral artery rings pre-contracted with phenylephrine (1 μM). The results showed the concentration-dependent induction of vasodilation by tofogliflozin, a response that remained unchanged following endothelial removal, pretreatment with the nitric oxide synthase inhibitor L-NAME (100 μM), or the inhibition of low- and intermediate-conductance Ca²⁺-activated K⁺ channels using apamin (1 μM) in combination with TRAM-34 (1 μM). Furthermore, pretreatment with the voltage-dependent K⁺ (Kv) channel inhibitor 4-AP (3 mM) reduced the vasodilatory effects of tofogliflozin whereas pretreatment with the ATP-sensitive K⁺ channel inhibitor glibenclamide (10 μM) or the large-conductance Ca²⁺-activated K⁺ channel inhibitor paxilline (1 μM) did not. Notably, our findings indicated that Kv7.X, rather than Kv1.5 or Kv2.1, is the primary Kv subtype involved in tofogliflozin-induced vasodilation. The vasodilatory effects of tofogliflozin were also significantly inhibited in femoral arterial rings pretreated with the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pump inhibitors thapsigargin (1 μM) and cyclopiazonic acid (10 μM). Tofogliflozin-induced vasodilation was unaltered in arterial rings exposed to the adenylyl cyclase inhibitor SQ 22536 (50 μM), the protein kinase A (PKA) inhibitor KT 5720 (1 μM), and the protein kinase G inhibitor KT 5823 (1 μM) whereas it was effectively reduced by the soluble guanylyl cyclase (sGC) inhibitor ODQ (10 μM). These findings suggest that tofogliflozin-induced vasodilation is mediated by the activation of the SERCA pump, the sGC/cGMP pathway, and Kv channels.

News (Medical) associated with Glyburide

28 Apr 2025

·www.globenewswire.com

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026. “The NDA submission for ET-600 is another important milestone for Eton, and for the thousands of children impacted by diabetes insipidus. If approved, ET-600 will be the only FDA-approved oral liquid formulation of desmopressin, providing the small, precise, and titratable doses required to treat pediatric patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long expressed a need for this product, and we’re pleased to be one step closer to bringing it to patients. Pre-launch commercial activities are already underway as we plan for a potential approval in the first quarter of 2026.” Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-600, which expires in 2044 and has additional patent applications under review. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. The company estimates that central diabetes insipidus impacts approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc.

NDA

28 Apr 2025

·ir.etonpharma.com

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) | Eton Pharmaceuticals, Inc.

News Release Details « Back to news Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026. “The NDA submission for ET-600 is another important milestone for Eton, and for the thousands of children impacted by diabetes insipidus. If approved, ET-600 will be the only FDA-approved oral liquid formulation of desmopressin, providing the small, precise, and titratable doses required to treat pediatric patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long expressed a need for this product, and we’re pleased to be one step closer to bringing it to patients. Pre-launch commercial activities are already underway as we plan for a potential approval in the first quarter of 2026.” Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-600, which expires in 2044 and has additional patent applications under review. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. The company estimates that central diabetes insipidus impacts approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

NDA

01 Apr 2025

·www.globenewswire.com

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S.DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”). “Esteve shares Eton’s dedication to putting patients first and we’re excited to partner with them to distribute this important treatment outside of the U.S. Esteve has the global infrastructure and established presence necessary to successfully commercialize Increlex in countries outside the U.S. This transaction will allow Eton to focus its efforts on the Company’s compelling growth opportunities within the U.S., including its three rare disease product launches planned for 2025, and eliminates the need for significant infrastructure investments that would have been required to commercialize Increlex outside the U.S.,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Esteve will license the ex-U.S. rights for up to ten years and will also be receiving an option to acquire the international rights in the future. Eton will supply product to Esteve at a fixed transfer price, and the transaction does not impact the Company’s expectation to exit 2025 at an approximately $80 million annual revenue run rate. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc.

License out/in

100 Deals associated with Glyburide

External Link

KEGG	Wiki	ATC	Drug Bank
D00336	Glyburide	A10BB01	DB01016

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
6q24-Related Transient Neonatal Diabetes Mellitus	Iceland	Ammtek Ltd.	24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus	European Union	Ammtek Ltd.	24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus	Norway	Ammtek Ltd.	24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus	Liechtenstein	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	Liechtenstein	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	Iceland	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	European Union	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	Norway	Ammtek Ltd.	24 May 2018
Diabetes Mellitus	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Diabetes Mellitus, Type 2	Japan	Taiyo Pharma Co., Ltd.	02 Mar 1971

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Infarction	Phase 1	Croatia	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Lithuania	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Spain	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Russia	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Canada	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Switzerland	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	France	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Finland	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Belgium	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Brain Infarction	Phase 1	Japan	Remedy Pharmaceuticals, Inc.	29 Aug 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PROSPERO CRD42024548600 (AAN2025)	Not Applicable	Brain Edema	1,501	Glyburide	wbmgqviasu(bhoiufbbpg) = Glyburide increased SAEs (OR=1.35 [1.02-1.79]; p=0.03) wllvklmjgd (vhtfoxoruh ) View more	Negative	07 Apr 2025
				Placebo/Standard of Care
AAN2025	Not Applicable	Subarachnoid Hemorrhage	419	Glibenclamide	kvedgawfhz(vevbmpzlcg): OR = 0.52 (95% CI, 0.31 - 0.89), P-Value = 0.017 View more	Positive	07 Apr 2025
				Placebo
NCT02864953 (CHARM, Pubmed \| Lancet Neurol)	Phase 3	Brain Edema	535	Intravenous glibenclamide 8.6 mg	zqaoapttjf(ltskhnnlzw) = monmsewgym dfsnemqzix (etlhzzsdqj )	Negative	01 Dec 2024
				Placebo	zqaoapttjf(ltskhnnlzw) = pxvlwjqdzz dfsnemqzix (etlhzzsdqj )
NCT03029702 (MATCh-GDM, CTgov)	Phase 4	Diabetes, Gestational \| Pregnancy in Diabetics	54	Insulin+Metformin+Glyburide (Usual Care)	usdyumnkml(imethehlto) = oxfqaxohzi hczkbvcymi (zadzgrbevn, sxpdebdpfq - lkfjauvgwp) View more	-	29 Nov 2024
				Insulin+Metformin+Glyburide (Individualized Treatment)	usdyumnkml(imethehlto) = mzjzkynlwi hczkbvcymi (zadzgrbevn, jsodjfqjxn - xccvjqywrl) View more
NCT02864953 (CHARM, PRNewswire) Manual	Phase 3	Stroke	535	CIRARA	(tbluuixwnh): OR = 2.22, P-Value = 0.03	Positive	01 Oct 2024
				placebo
NCT02864953 (CHARM, PRNewswire) Manual	Phase 3	Brain Infarction	535	CIRARA	(yosnrhfwag): OR = 1.8, P-Value = 0.01 View more	Positive	03 Sep 2024
				Placebo
NCT05137678 (Pubmed \| Neurocrit Care)	Phase 4	Aneurysm, Intracranial Berry, 1 serum neuron-specific enolase (NSE) \| soluble protein 100B (S100B)	111	Glibenclamide tablet 3.75 mg/day	kujurklzhc(mzyiqdzbss) = azhzskyyqu cczzlrxugu (xfypdwzurn )	Negative	08 Aug 2024
				Glibenclamide (Control group)	kujurklzhc(mzyiqdzbss) = utpvwexdse cczzlrxugu (xfypdwzurn )
NCT02864953 (CHARM, PRNewswire) Manual	Phase 3	Brain Infarction	535	BIIB093	(fdfbomfiqg) = statistically significant improvements in functional outcomes (Odds Ratio 1.66, p=0.03). ziouxlilby (tgvnvatbyo )	Positive	29 May 2024
				Placebo
NCT02864953 (CHARM, CTgov)	Phase 3	Brain Infarction \| Brain Edema	535	Placebo (Placebo)	fhrncbfgby(vurmhtzjcd) = cznngomxtv urhqozlacf (ajackgjgup, uowpnbgqvp - bateojfonr) View more	-	09 Jan 2024
				BIIB093 (BIIB093)	fhrncbfgby(vurmhtzjcd) = hnexejlwvm urhqozlacf (ajackgjgup, jlvcentbwl - ypetfjuexa) View more
NCT00965991 (CTgov)	Not Applicable	Diabetes, Gestational	149	Metformin (Metformin)	kxwtgmshtt(emkifxwany) = xnyroovgjm cshzjewdks (whwualqhvp, lrdqqbmtyn - iuykxdapnl)	-	21 Dec 2023
				Glyburide (Glyburide)	kxwtgmshtt(emkifxwany) = zpqicdglzl cshzjewdks (whwualqhvp, cmoxatkjtv - ndieathfkl)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis